Student Resources | Faculty, Postdoc, & Staff Resources
Search for:
Login

Posts classified under: Affinity Groups

HomeUCLA Brain Research Institute (BRI)  > People  > Affinity Groups
Laura DeNardo, Ph.D.

Laura DeNardo, Ph.D.

Publications

A selected list of publications:

Laura A DeNardo, Cindy D Liu, William E Allen, Eliza L Adams, Drew Friedmann, Ehsan Dadgar-Kiani, Lisa Fu, Casey J Guenthner, Jin Hyung Lee, Marc Tessier-Lavigne, Liqun Luo   Temporal Evolution of Cortical Ensembles Promoting Remote Memory Retrieval , 2018; .
Berns Dominic S, DeNardo Laura A, Pederick Daniel T, Luo Liqun   Teneurin-3 controls topographic circuit assembly in the hippocampus Nature, 2018; 554(7692): 328-333.
Savas Jeffrey N, Wang Yi-Zhi, DeNardo Laura A, Martinez-Bartolome Salvador, McClatchy Daniel B, Hark Timothy J, Shanks Natalie F, Cozzolino Kira A, Lavallée-Adam Mathieu, Smukowski Samuel N, Park Sung Kyu, Kelly Jeffery W, Koo Edward H, Nakagawa Terunaga, Masliah Eliezer, Ghosh Anirvan, Yates John R   Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer’s Disease-like Pathology Cell reports, 2017; 21(9): 2614-2627.
Allen William E, DeNardo Laura A, Chen Michael Z, Liu Cindy D, Loh Kyle M, Fenno Lief E, Ramakrishnan Charu, Deisseroth Karl, Luo Liqun   Thirst-associated preoptic neurons encode an aversive motivational drive Science (New York, N.Y.), 2017; 357(6356): 1149-1155.
DeNardo Laura, Luo Liqun   Genetic strategies to access activated neurons Current opinion in neurobiology, 2017; 45(6356): 121-129.
Savas JN, Ribeiro LF, Wierda KD, Wright R, DeNardo-Wilke LA, Chamma I, Wang Yi-Zhi, Zemla R, Lavallee- Adam M, Vennekens KM, O’Sullivan ML, Antonios JK, Hall EA, Thoumine O, Attie AD, Yates JR, Ghosh A, De Wit J   The Sorting Receptor SorCS1 Regulates Trafficking of Neurexin and AMPA receptors, Neuron, 2015; 87: 764-80.
DeNardo Laura A, Berns Dominic S, DeLoach Katherine, Luo Liqun   Connectivity of mouse somatosensory and prefrontal cortex examined with trans-synaptic tracing Nature neuroscience, 2015; 18(11): 1687-1697.
DeNardo Laura A, de Wit Joris, Otto-Hitt Stefanie, Ghosh Anirvan   NGL-2 regulates input-specific synapse development in CA1 pyramidal neurons Neuron, 2012; 76(4): 762-75.
Wilke Scott A, Hall Benjamin J, Antonios Joseph K, Denardo Laura A, Otto Stefanie, Yuan Bo, Chen Fading, Robbins Elissa M, Tiglio Katie, Williams Megan E, Qiu Zilong, Biederer Thomas, Ghosh Anirvan   NeuroD2 regulates the development of hippocampal mossy fiber synapses Neural development, 2012; 7(4): 9.
Timothy F. Cloughesy, M.D.

Timothy Cloughesy, M.D.

Publications

A selected list of publications:

Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC   EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells Cancer biology & therapy. , 2004; 3(12): 1243-9.
Graham CA, Cloughesy TF   Brain tumor treatment: chemotherapy and other new developments Seminars in oncology nursing. , 2004; 20(4): 260-72.
Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD   Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs Investigational new drugs. , 2004; 22(4): 427-35.
Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M   Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2004; 22(21): 4282-9.
Mischel PS, Cloughesy TF, Nelson SF   DNA-microarray analysis of brain cancer: molecular classification for therapy Nature reviews. Neuroscience. , 2004; 5(10): 782-92.
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF   Gene expression profiling of gliomas strongly predicts survival Cancer research. , 2004; 64(18): 6503-10.
Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, Goldman J   Prediction of neurocognitive outcome in adult brain tumor patients Journal of neuro-oncology. , 2004; 67(1-2): 245-53.
Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS   p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition Oncogene. , 2004; 23(6): 1283-90.
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T   A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma Journal of neuro-oncology. , 2004; 66(3): 365-75.
Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J   Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro-oncology. , 2004; 6(1): 44-54.
Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS   Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line Laboratory investigation; a journal of technical methods and pathology. , 2004; 84(1): 8-20.
Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF   Gene expression profiling identifies molecular subtypes of gliomas Oncogene. , 2003; 22(31): 4918-23.
Mischel PS, Nelson SF, Cloughesy TF   Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy Cancer biology & therapy. , 2003; 2(3): 242-7.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Metastatic NSCLC Radiographics : a review publication of the Radiological Society of North America, Inc. , 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma Radiographics, 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Patient’s symptoms not related to the lesion seen in the MR images Radiographics, 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess Radiographics : a review publication of the Radiological Society of North America, Inc. , 2003; 23(6): 1591-611.
Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M   Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2003; 21(12): 2305-11.
Mischel PS, Cloughesy TF   Targeted molecular therapy of GBM Brain Pathol, 2003; 13(1): 52-61.
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS   Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer research. , 2003; 63(11): 2742-6.
Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL   Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer. , 2003; 97(9 Suppl): 2381-6.
Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF   Identification of molecular subtypes of glioblastoma by gene expression profiling Oncogene. , 2003; 22(15): 2361-73.
Stephen Caldwell Cannon, M.D., Ph.D.

Steve Cannon, M.D., Ph.D.

Biography

The primary research interests of our laboratory are how ion channels regulate the electrical excitability of cells and how defects in these channels lead to human disease. In the past two decades, mutations of ion channel genes have been found to be the primary cause for over 100 human diseases. Our research program is focused on the mechanistic basis for a group of inherited conditions that alter the electrical excitability of skeletal muscle, including periodic paralysis and myotonia. We have characterized the gating defects of mutant channels, generated computational models of muscle excitability, and produced genetically-engineered mice to gain insights on the pathomechanisms of these disorders and to explore therapeutic interventions.

1 … 11 12 13 14 15 … 36